Stay updated on Pembrolizumab in NK/T & EBV+ DLBCL: Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in NK/T & EBV+ DLBCL: Clinical Trial page.
Latest updates to the Pembrolizumab in NK/T & EBV+ DLBCL: Clinical Trial page
- Check7 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference1.0%
- Check14 days agoChange DetectedThe website has updated the contact details section for the study, clarifying that it now provides information for individuals who can answer questions about joining the study and includes a reference to the Contacts and Locations section.SummaryDifference4%
- Check21 days agoChange DetectedDifference0.7%
- Check29 days agoChange DetectedNew features have been added to the website, while several options related to participant groups, interventions, and data download formats have been removed.SummaryDifference6%
- Check36 days agoChange DetectedSeveral key health-related resources, including links to MedlinePlus and various rare disease pages, have been removed from the website.SummaryDifference0.7%
- Check43 days agoChange DetectedThe website has been updated to version 2.12.2, with new resources added related to lymphoma and treatments, including links to MedlinePlus and various rare disease information pages.SummaryDifference7%
Stay in the know with updates to Pembrolizumab in NK/T & EBV+ DLBCL: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in NK/T & EBV+ DLBCL: Clinical Trial page.